Below are the financial statements of Madrigal Pharmaceuticals, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 |
|---|---|---|
| Revenues | — | — |
| Product revenue, net | 180.13a | 0a |
| Operating expenses | — | — |
| Cost of sales | -6.23a | 0a |
| Research and development | -236.72a | -272.35a |
| Selling, general and administrative | -435.06a | -108.15a |
| Total operating expenses | -678.01a | -380.5a |
| Loss from operations | -497.88a | -380.5a |
| Interest income | 46.65a | 19.58a |
| Interest expense | -14.67a | -12.71a |
| Net loss | -465.89a | -373.63a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.